Multiple Sclerosis

Detailed Overview

The disease manifests as episodic neurological deficits (relapses) that typically evolve into a progressive decline over time. The pathology involves autoreactive T cells crossing the blood-brain barrier, triggering an inflammatory cascade that damages oligodendrocytes. Plaques or lesions form in the white and grey matter. MS presents heterogeneously with visual, motor, sensory, and autonomic symptoms.

Epidemiology & Demographics

Prevalence is roughly 1 in 1000 in North America and Northern Europe. Median age of onset is 28-31 years. Women are affected 2.5 to 3 times more frequently than men.

Etiological Mechanism

Considered a complex interplay of genetic susceptibility (HLA-DRB1*1501 allele) and environmental triggers (Epstein-Barr Virus infection, low Vitamin D levels, smoking).

Primary Causes

An autoimmune response targeting central nervous system antigens (e.g., myelin basic protein), initiated by molecular mimicry or bystander activation after viral infections.

• Epstein-Barr Virus (EBV): History of EBV infection/mononucleosis significantly increases risk; MS is rare in EBV-seronegative individuals.
• Vitamin D Deficiency: Lower serum 25-hydroxyvitamin D levels and residing at higher latitudes (less UV exposure) are associated with higher risk.
• Genetics: Presence of HLA-DRB1*15:01 allele confers a 3-fold increased risk.

Autoreactive CD4+ Th1 and Th17 cells breach the blood-brain barrier and secrete pro-inflammatory cytokines (IFN-gamma, IL-17). This recruits macrophages and B cells. Macrophages strip myelin from axons. B cells produce oligoclonal immunoglobulins. Myelin loss impairs saltatory conduction, causing conduction block. Over time, chronic inflammation leads to irreversible axonal transection and brain atrophy.

Characteristic Clinical Presentation

• Optic Neuritis: Unilateral painful vision loss, impaired color vision, and central scotoma.
• Sensory abnormalities: Paresthesias, numbness, or a tight banding sensation around the trunk (MS hug).
• Motor weakness: Asymmetric limb weakness, spasticity, and hyperreflexia.
• Fatigue: Severe, disabling lassitude often worsened by heat (Uhthoff's phenomenon).

Physical Examination Signs

• Lhermitte's sign: Electric shock-like sensation radiating down the spine upon neck flexion.
• Relative afferent pupillary defect (Marcus Gunn pupil) secondary to optic neuritis.
• Intention tremor, dysmetria, and scanning speech (Charcot's neurologic triad).

• Neurogenic Bladder: Detrusor hyperreflexia leading to urgency, incontinence, and frequent UTIs.
• Cognitive Impairment: Deficits in information processing speed, memory, and executive function in up to 50% of patients.
• Depression: High prevalence of major depressive disorder, partly biological and partly psychosocial.

Diagnostic Criteria & Guidelines

Diagnosis is based on the McDonald Criteria (2017 revision), requiring evidence of dissemination in space (DIS) - >=1 T2 lesion in >=2 of 4 MS-typical regions (periventricular, cortical/juxtacortical, infratentorial, spinal cord) AND dissemination in time (DIT) - simultaneous presence of enhancing and non-enhancing lesions, or a new lesion on follow-up MRI, or CSF-specific oligoclonal bands.

Differential Diagnosis

• Neuromyelitis Optica Spectrum Disorder (NMOSD)
• Acute Disseminated Encephalomyelitis (ADEM)
• Neurosarcoidosis
• Lyme Disease

Laboratory Tests & Biomarkers

• Cerebrospinal Fluid (CSF) Analysis: Presence of >= 2 oligoclonal IgG bands absent in serum; elevated IgG index.
• Serum Aquaporin-4 IgG: Negative (used to rule out NMOSD).
• Serum Vitamin D (25-OH): Often low (< 30 ng/mL).

Imaging Modalities & Findings

• Brain MRI with/without contrast:
• Spinal Cord MRI:

• Relapsing-Remitting MS (RRMS)
  Discrete attacks of neurological dysfunction followed by complete or partial recovery. ~85% of cases at onset.
• Secondary Progressive MS (SPMS)
  Gradual neurological decline following an initial relapsing-remitting course.
• Primary Progressive MS (PPMS)
  Continuous neurological decline from disease onset without distinct relapses. ~15% of cases.

Second-Line & Adjunctive Therapy

Alemtuzumab (12 mg/day IV for 5 days year 1, 3 days year 2) or Cladribine. Autologous hematopoietic stem cell transplantation (aHSCT) for aggressive, treatment-refractory relapsing disease.

Surgical & Procedural Management

Rarely indicated for MS directly. Intrathecal baclofen pump placement for severe, medically refractory spasticity.

Recommended Lifestyle Changes

• Smoking cessation is critical, as smoking accelerates disease progression.
• Vitamin D3 supplementation (2000-5000 IU/day) to maintain serum levels 40-60 ng/mL.
• Regular aerobic exercise to manage fatigue and spasticity.

Patient Counseling & Advice

Counsel on avoiding extreme heat, which can temporarily exacerbate symptoms (Uhthoff phenomenon). Discuss family planning, as some DMTs (teriflunomide, cladribine) are highly teratogenic.

Follow-Up & Monitoring Schedule

Annual brain MRI (and spinal cord MRI if symptomatic) to assess for silent radiological activity. John Cunningham (JC) virus serology every 6 months if on Natalizumab to assess PML risk.

Preventive Strategies

Adequate vitamin D supplementation in childhood and adolescence, preventing childhood obesity, and avoiding smoking.

Life expectancy is reduced by approximately 7 years compared to the general population. 50% of patients require a walking aid 15 years after diagnosis if untreated, but outcomes have drastically improved with modern DMTs.